AR125059A1 - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
AR125059A1
AR125059A1 ARP220100537A ARP220100537A AR125059A1 AR 125059 A1 AR125059 A1 AR 125059A1 AR P220100537 A ARP220100537 A AR P220100537A AR P220100537 A ARP220100537 A AR P220100537A AR 125059 A1 AR125059 A1 AR 125059A1
Authority
AR
Argentina
Prior art keywords
estrogen receptor
degraders
selective
selective degraders
formula
Prior art date
Application number
ARP220100537A
Other languages
English (en)
Inventor
Kenneth Charles Cassidy
Kishore Kumar Katyayan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR125059A1 publication Critical patent/AR125059A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula: (1) y sales aceptables desde el punto de vista farmacéutico de este y composiciones farmacéuticas del mismo, en donde R se selecciona de compuestos de fórmula (2) o (3).
ARP220100537A 2021-03-16 2022-03-09 Degradadores selectivos del receptor de estrógeno AR125059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163161531P 2021-03-16 2021-03-16

Publications (1)

Publication Number Publication Date
AR125059A1 true AR125059A1 (es) 2023-06-07

Family

ID=81325828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100537A AR125059A1 (es) 2021-03-16 2022-03-09 Degradadores selectivos del receptor de estrógeno

Country Status (12)

Country Link
US (1) US11744844B2 (es)
EP (1) EP4308581A1 (es)
JP (1) JP2024511352A (es)
KR (1) KR20230145160A (es)
CN (1) CN116981679A (es)
AR (1) AR125059A1 (es)
AU (1) AU2022240454B2 (es)
CA (1) CA3208671C (es)
IL (1) IL305377A (es)
MX (1) MX2023010823A (es)
TW (1) TW202300492A (es)
WO (1) WO2022197528A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150056A1 (en) 2022-02-01 2023-08-10 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE476428T1 (de) 2004-01-22 2010-08-15 Lilly Co Eli Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
IL305377A (en) 2023-10-01
AU2022240454A1 (en) 2023-08-24
US20220296624A1 (en) 2022-09-22
CN116981679A (zh) 2023-10-31
AU2022240454B2 (en) 2024-04-18
CA3208671A1 (en) 2022-09-22
JP2024511352A (ja) 2024-03-13
MX2023010823A (es) 2023-09-28
US11744844B2 (en) 2023-09-05
TW202300492A (zh) 2023-01-01
EP4308581A1 (en) 2024-01-24
KR20230145160A (ko) 2023-10-17
CA3208671C (en) 2024-04-02
WO2022197528A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
AR115694A1 (es) Degradadores selectivos del receptor de estrógeno
MX2022014458A (es) Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
NO20085077L (no) Nye forbindelser
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
CO2022011065A2 (es) Agonistas heterocíclicos de glp-1
MXPA05009985A (es) Ligandos de receptores de canabinoides.
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
SE0302192D0 (sv) Novel compounds
PA8495101A1 (es) Derivados de 13-metileritromicina
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
CL2020001817A1 (es) Moduladores del receptor c5a
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
AR045159A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
AR125059A1 (es) Degradadores selectivos del receptor de estrógeno
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
MX2021011376A (es) Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo